Nafiseh Hashemi, MD
Neuro-ophthalmology · Encino, CANPI 1619264645
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,908 of the $12,013 with a category attached, or 82.5%. 28 manufacturers reported payments, led by Amgen at 29.7% of the total.
Across 333 payments — averaging $36.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$1K
- AstraZeneca$978
- Bausch & Lomb Americas Inc.$836
- Merz Pharmaceuticals, LLC$615
- plus $3K from 22 others
What the payments were for
- Travel & lodging$1,40112%
- Food & beverage$9,90882%
- Education$6656%
- Gifts$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 134 | $3,569 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $1,635 |
| Alcon | 22 | $1,028 |
| AstraZeneca | 21 | $978 |
| Bausch & Lomb Americas Inc. | 18 | $836 |
| Merz Pharmaceuticals, LLC | 19 | $615 |
| Sun Pharmaceutical Industries Inc. | 15 | $498 |
| AbbVie(2 entities) | 19 | $320 |
| Aerie Pharmaceuticals, Inc. | 3 | $267 |
| Novartis | 10 | $256 |
| Dompe US, Inc. | 8 | $238 |
| Merz North America, Inc. | 7 | $232 |
| Tarsus Pharmaceuticals, Inc. | 8 | $223 |
| Catalyst Pharmaceuticals, Inc. | 3 | $195 |
| Oyster Point Pharma, Inc. | 8 | $174 |
| Akorn Operating Company LLC | 8 | $150 |
| Kala Pharmaceuticals, Inc. | 4 | $143 |
| Biogen | 1 | $135 |
| EMD Serono, Inc. | 1 | $119 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Pfizer | 2 | $55 |
| UCB, Inc. | 2 | $52 |
| Shire North American Group Inc | 2 | $46 |
| Akorn, Inc. | 2 | $44 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Springworks Therapeutics, Inc. | 1 | $27 |
| Thea Pharma Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 6 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,516
- Tecnis Multifocal Family of 1-piece IOLS$1,516
- Tecnis Symfony IOL$1,516
- UPLIZNA$851
- Rocklatan$370
- TEPEZZA$303
- Rhopressa$247
- MIEBO$246
- XIIDRA$246
- SOLIRIS$244
- VYZULTA$225
- Clareon$148
- Clareon PanOptix Pro$137
- TYSABRI$135
- LOTEMAX SM$125
- ULTOMIRIS$122
- CEQUA$122
- FIRDAPSE$111
- AcrySof IQ PanOptix UV IOL$104
How this compares
$12,013 in reported general payments places this provider in the 80th percentile of 25 neuro-ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 231 | $166,069 |
| Cyclosporine | 356 | $110,534 |
| XiidraLifitegrast | 55 | $37,279 |
| Restasis MultidoseCyclosporine | 45 | $27,092 |
| MieboPerfluorohexyloctane/Pf | 20 | $15,325 |
| Nurtec OdtRimegepant Sulfate | 12 | $10,717 |
| Prednisolone Acetate | 223 | $9,610 |
| EysuvisLoteprednol Etabonate | 18 | $9,327 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $8,427 |
| ProlensaBromfenac Sodium | 19 | $6,273 |
| LumiganBimatoprost | 17 | $5,800 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 141 | $5,475 |
| Loteprednol Etabonate | 28 | $5,147 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $4,882 |
| Lotemax SmLoteprednol Etabonate | 19 | $4,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Combigan, Lumigan | $320 | $207,388330 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $836 | $52,60575 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $100 | $16,10266 claims |
| PfizerNurtec Odt | $55 | $10,71712 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $143 | $9,32718 claims |
| AlconSimbrinza | $1,028 | $4,88226 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $267 | $4,56614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 neuro-ophthalmology providers in California.
Other neuro-ophthalmology in Encino
- Benjamin GhiamEncino$3K
- Kimberly CockerhamSan Diego$183K
- Vivek PatelIrvine$81K
- Kimberly GokoffskiOrange$36K
- Syed Khizer KhaderiStanford$35K
- Yin LiuSacramento$11K
- Samuel SpiegelPasadena$8K
- Howard KraussLos Angeles$7K
- Heather MossStanford$4K
- Frank Abella AyalaLos Angeles$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.